annb0t
Top 20
Travere Therapeutics, Inc.
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial
SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion â¥1.0 g/day (or urine protein-to-creati...
>>> Read more: Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
Temporary marketing authorization is based on statistically significant and clinically meaningful results from the Phase 3 PROTECT Trial
SAN DIEGO, Oct. 17, 2024 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc., (Nasdaq: TVTX) and CSL Vifor today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy (IgAN) with a urine protein excretion â¥1.0 g/day (or urine protein-to-creati...
>>> Read more: Travere Therapeutics and CSL Vifor Announce Swissmedic Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy
